Key Insights

Highlights

Success Rate

87% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

9.3%

4 terminated out of 43 trials

Success Rate

86.7%

+0.2% vs benchmark

Late-Stage Pipeline

21%

9 trials in Phase 3/4

Results Transparency

23%

6 of 26 completed with results

Key Signals

6 with results87% success

Data Visualizations

Phase Distribution

34Total
Not Applicable (13)
P 1 (3)
P 2 (9)
P 3 (8)
P 4 (1)

Trial Status

Completed26
Recruiting4
Terminated4
Not Yet Recruiting3
Unknown3
Withdrawn2

Trial Success Rate

86.7%

Benchmark: 86.5%

Based on 26 completed trials

Clinical Trials (43)

Showing 20 of 20 trials
NCT06672237Phase 3Recruiting

A Phase 3 Study of NTLA-2001 in ATTRv-PN

NCT07475065Phase 2Not Yet Recruiting

The Effect of Oral DLBS1033 in Patients With Diabetic Polyneuropathy

NCT04800484Not ApplicableRecruiting

The Effects of AFO Heel Height and Stiffness on Gait

NCT03651609Not ApplicableCompletedPrimary

Treatment for Ulnar Neuropathy at the Elbow

NCT06890208Recruiting

Chronical Illness-related Limitations of the Ability to Cope With Rising Temperatures, Third Wave

NCT03913689Completed

StimRouter Registry Clinical Protocol

NCT06835634Active Not Recruiting

Progressive Advancements in Neurosurgery, Data and Analysis Database

NCT06407154Completed

Chronical Illness-related Limitations of the Ability to Cope with Rising Temperatures: an Observational Study, 2nd Wave

NCT05777499Not ApplicableRecruiting

MUSic Therapy In Complex Specialist Neurorehabilitation

NCT05229042Phase 1CompletedPrimary

A Study to Investigate the Safety and Efficacy of Ricolinostat

NCT05961163Terminated

Chronical Illness-related Limitations of the Ability to Cope With Rising Temperatures: an Observational Study

NCT05193851Phase 1CompletedPrimary

Evaluate the Safety and Pharmacokinetics of Ricolinostat

NCT05133947CompletedPrimary

Pre-study to Evaluate IENFD Induction in Patients With Taxane-induced CIPN

NCT03870295Not ApplicableCompletedPrimary

Technique to Measure Type C Fibre Nerve Conduction Velocitynerve Fibers in Polyneuropathies

NCT02552277Phase 2Completed

A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy

NCT00050271Not ApplicableCompleted

Acetyl-L-Carnitine for the Treatment of NRTI-Associated Peripheral Neuropathy

NCT04014244Not ApplicableUnknownPrimary

Dextrose, Corticosteroids and Surgical Release in Carpal Tunnel Syndrome

NCT02654691CompletedPrimary

Chronic Neuropathy Following Chemotherapy

NCT03109301Phase 2Withdrawn

Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)

NCT01465620Phase 3CompletedPrimary

Dietetic and Hygiene Measures in Metabolic Neuropathies: the Neurodiet Study

Scroll to load more

Research Network

Activity Timeline